Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phalaris minor pollen extract is an allergenic biological product used for the diagnosis and treatment of Type I hypersensitivity reactions. As a diagnostic agent, it is utilized in skin prick testing to identify sensitization in patients presenting with allergic rhinitis, conjunctivitis, or asthma. In a therapeutic context, it is employed in allergen-specific immunotherapy (AIT), where gradual exposure to increasing doses of the pollen extract induces immunological tolerance. The mechanism involves shifting the immune response from a Th2-dominated profile to a Th1/Treg profile, increasing the production of allergen-specific IgG4 (blocking antibodies), and reducing mast cell and basophil reactivity to the allergen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phalaris minor pollen.